Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

Loren Michel, Douglas R. Adkins, Tanya M. Wildes et al.|Oral Oncology|2016

Cited by 88